A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Study Summary

This is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab or standard-of-care treatments in participants with refractory metastatic colorectal cancer.

Conditions

Metastatic Colorectal Cancer

Interventions / Drugs

Botensilimab Balstilimab Standard of Care

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment234 participants

Primary Completion—

Lead SponsorAgenus Inc.

Data Retrieved2026-04-11 02:52:45.212095+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.